title: Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer.
abstract: OBJECTIVE
  We evaluated the prognostic value of type 2 diabetes mellitus (DM) in patients treated surgically for localized renal cell carcinoma (RCC).
  
  
  METHODS
  Between 1995 and 2011, 588 patients with renal tumor diagnoses were treated surgically and 492 patients with pathologically confirmed nonmetastatic RCC diagnoses were included in the study. The associations of clinical and pathologic parameters with a type 2 DM diagnosis were evaluated. Kaplan-Meier estimations for disease-specific survival (DSS) and overall survival (OS) were generated according to type 2 DM diagnosis, and the log-rank test was used to compare survival according to the variables.
  
  
  RESULTS
  The mean age of the patients was 56.7±12 years (range, 15 to 84 years; median, 58 years) and the mean length of follow-up was 35.9±28 months (range, 1 to 145 months; median, 34.3 months). Of the 492 patients, 62 (12.6%) had a diagnosis of DM at the time of surgery (group I) and 430 did not have DM (group II). The mean age and the incidence of clear cell RCC histological subtype were significantly higher in group I than in group II (p<0.001 and p=0.036, respectively). Although DSS and OS were lower in group I, this difference was not significant. Type 2 DM was not detected as an independent prognostic factor for DSS and OS.
  
  
  CONCLUSIONS
  This study investigated the role and effect of DM on the prognosis of localized RCC that was treated surgically. The present study did not detect DM as an independent prognostic factor for RCC.
authors: Department of Urology, Ankara University School of Medicine, Ankara, Turkey.
authors: Evren
authors: E
authors: Süer
authors: Erdem
authors: E
authors: Oztürk
authors: Omer
authors: O
authors: Gülpınar
authors: Aytaç
authors: A
authors: Kayış
authors: Sümer
authors: S
authors: Baltacı
keywords: Prognosis; Renal cell carcinoma; Type 2 diabetes mellitus
references: Ann Oncol. 2007 Mar;18(3):596-600
references: 17158772
references: Scand J Surg. 2004;93(2):88-96
references: 15285559
references: Am J Epidemiol. 2004 Dec 15;160(12):1168-76
references: 15583369
references: J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5
references: 9308706
references: Diabetes Metab J. 2011 Jun;35(3):193-8
references: 21785737
references: N Engl J Med. 2000 Nov 2;343(18):1305-11
references: 11058675
references: Annu Rev Public Health. 2006;27:465-90
references: 16533126
references: Diabetologia. 1999 Jan;42(1):107-12
references: 10027588
references: Acta Diabetol. 2010 Jun;47(2):87-95
references: 20376506
references: J Clin Invest. 1990 Nov;86(5):1503-10
references: 2243127
references: Int J Epidemiol. 1990 Dec;19(4):832-8
references: 2084009
references: Int J Urol. 2007 May;14(5):393-7
references: 17511719
references: Diabetes Care. 2002 Sep;25(9):1551-6
references: 12196426
references: Br J Cancer. 2005 Jun 6;92(11):2076-83
references: 15886696
references: JAMA. 2006 Apr 5;295(13):1549-55
references: 16595758
references: Urol Oncol. 2013 Oct;31(7):1310-5
references: 22281433
references: Diabetes Care. 2011 Jul;34(7):1552-6
references: 21602426
references: Eur Urol. 2010 Sep;58(3):398-406
references: 20633979
references: Cancer Sci. 2010 May;101(5):1073-9
references: 20345478
references: Am J Epidemiol. 1991 Nov 1;134(9):942-7
references: 1951291
references: Diabetologia. 2007 Jul;50(7):1365-74
references: 17476474
references: J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
references: 16985252
references: J Cancer. 2012;3:42-8
references: 22232697
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
references: 22187469
references: J Natl Cancer Inst. 2005 Nov 16;97(22):1679-87
references: 16288121